Tvardi Therapeutics, Inc. filed a Form 8-K on November 19, 2026, disclosing that it issued a press release announcing its next-generation oral STAT3 inhibitor TTI-109 is advancing toward an Investigational New Drug application in inflammatory bowel disease following FDA pre-IND feedback.

Key Highlights

  • Program advance: Tvardi Therapeutics disclosed that TTI-109, its oral STAT3 inhibitor, is advancing toward an IND filing in inflammatory bowel disease.
  • FDA interaction: The advance follows FDA pre-IND feedback, as described in the press release attached as Exhibit 99.1.
  • Disclosure date: The press release was issued on November 19, 2026, the same date as the Current Report.
  • Furnishing basis: The information was furnished under Item 7.01 Regulation FD Disclosure and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
  • Signatory: The report was signed by Imran Alibhai, Chief Executive Officer of Tvardi Therapeutics, Inc.

Tvardi Therapeutics Discloses FDA Pre-IND Feedback on TTI-109 for Inflammatory Bowel Disease

According to the filing, Tvardi Therapeutics, Inc. (NASDAQ:TVRD) submitted a Current Report on Form 8-K dated November 19, 2026, under Item 7.01 Regulation FD Disclosure. The company disclosed the issuance of a press release titled "Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback." The full text of that press release was attached as Exhibit 99.1 and incorporated by reference into the report.

The filing states that the information furnished under Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended," and is not subject to the liabilities of that section. The company noted the information will not be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act except as expressly set forth by specific reference in such a filing.

Tvardi Therapeutics is a Delaware-incorporated company headquartered at 3 Sugar Creek Ctr. Blvd., Suite 525, Sugar Land, Texas 77478. The report was signed by Imran Alibhai in his capacity as Chief Executive Officer. No financial statements were included in this filing; the only exhibits listed are the press release (Exhibit 99.1) and the Cover Page Interactive Data File (Exhibit 104).

What Was Disclosed

Tvardi Therapeutics filed an 8-K on November 19, 2026, furnishing a press release under Regulation FD reporting that its oral STAT3 inhibitor TTI-109 is advancing toward an IND filing in inflammatory bowel disease after receiving FDA pre-IND feedback.